ATOSSA THERAPEUTICS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2011 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Atossa Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2011 to Q4 2024.
  • Atossa Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$6.35M, a 18.1% increase year-over-year.
  • Atossa Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$25.5M, a 15.3% increase year-over-year.
  • Atossa Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$25.5M, a 15.3% increase from 2023.
  • Atossa Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$30.1M, a 11.6% decline from 2022.
  • Atossa Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$27M, a 30.8% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$25.5M -$6.35M +$1.41M +18.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-25
Q3 2024 -$26.9M -$7.23M -$1M -16.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$25.9M -$6.05M +$3.78M +38.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$29.7M -$5.88M +$403K +6.42% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$30.1M -$7.75M -$263K -3.51% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-25
Q3 2023 -$29.8M -$6.23M +$1.78M +22.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$31.6M -$9.83M -$3.16M -47.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$28.5M -$6.28M -$1.5M -31.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$27M -$7.49M -$2.66M -55% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$24.3M -$8.01M -$2.81M -54.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$21.5M -$6.67M +$367K +5.21% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$21.9M -$4.79M -$1.25M -35.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$20.6M -$4.83M +$2.65M +35.4% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$23.3M -$5.2M -$1.71M -48.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$21.6M -$7.04M -$3.13M -80.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$18.4M -$3.54M -$591K -20% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$17.8M -$7.48M -$4.87M -186% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$13M -$3.49M -$205K -6.24% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$12.8M -$3.91M +$3.36M +46.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$16.1M -$2.95M +$1.13M +27.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
Q4 2019 -$17.2M -$2.62M -$540K -26% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$16.7M -$3.29M +$24K +0.72% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$16.7M -$7.26M -$3.12M -75.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-13
Q1 2019 -$13.6M -$4.07M -$2.2M -117% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-13
Q4 2018 -$11.4M -$2.08M -$85.1K -4.27% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-26
Q3 2018 -$11.3M -$3.31M -$1.13M -51.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$10.2M -$4.14M -$1.9M -84.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-13
Q1 2018 -$8.29M -$1.87M -$171K -10% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-13
Q4 2017 -$8.12M -$1.99M +$531K +21% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-28
Q3 2017 -$8.65M -$2.18M -$2.39M -1167% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$6.26M -$2.24M -$519K -30.1% Apr 1, 2017 Jun 30, 2017 10-Q/A 2018-11-13
Q1 2017 -$5.74M -$1.7M +$624K +26.8% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$6.37M -$2.52M +$2.44M +49.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 -$8.81M $205K +$4.52M Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$13.3M -$1.72M +$1.42M +45.2% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$14.8M -$2.33M +$1.01M +30.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q4 2015 -$15.8M -$4.96M +$851K +14.6% Oct 1, 2015 Dec 31, 2015 10-K/A 2017-03-21
Q3 2015 -$16.6M -$4.32M -$1.07M -33.1% Jul 1, 2015 Sep 30, 2015 10-Q/A 2017-03-21
Q2 2015 -$15.5M -$3.15M +$42.7K +1.34% Apr 1, 2015 Jun 30, 2015 10-Q/A 2017-03-21
Q1 2015 -$15.6M -$3.34M -$924K -38.3% Jan 1, 2015 Mar 31, 2015 10-Q/A 2017-03-21
Q4 2014 -$14.7M -$5.81M -$3.06M -111% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-30
Q3 2014 -$11.6M -$3.25M +$256K +7.32% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-12
Q2 2014 -$11.9M -$3.19M -$604K -23.4% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-06
Q1 2014 -$11.3M -$2.41M -$470K -24.2% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-13
Q4 2013 -$10.8M -$2.76M -$1.05M -61.7% Oct 1, 2013 Dec 31, 2013 10-K 2015-03-30
Q3 2013 -$9.73M -$3.5M -$2.36M -206% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-12
Q2 2013 -$7.37M -$2.58M -$1.42M -121% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-12
Q1 2013 -$5.96M -$1.94M -$879K -82.7% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-14
Q4 2012 -$5.08M -$1.71M Oct 1, 2012 Dec 31, 2012 10-K 2014-03-27
Q3 2012 -$1.14M +$129K +10.2% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-12
Q2 2012 -$1.17M Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 -$1.06M Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-15
Q3 2011 -$1.27M Jul 1, 2011 Sep 30, 2011 10-Q/A 2013-01-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.